SIBIA Neurosciences (SIBI) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : SIBIA Neurosciences (SIBI)

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Czechsinthemail who wrote (60)	8/26/1997 2:38:00 AM
From: Czechsinthemail	of 579

I'm reposting some questions raised by Peter Dale about SIB-1508Y that I couldn't answer but hoped someone else could: Since my training was in Neuroscience (glial expression of growth factors) and have not followed the field recently, I'm very curious about how SIB-1508Y works. Does it preserve nigral neurons? Does it inhibit the breakdown of Dopamine? In other words, has Sibia found a way to treat the disease or are they treating the symptoms (like L-dopa). My brief search indicates that one article has been published for this compound - since no abstract was available it appears its a nicotinic AchR agonist. So it must work downstream of the dopaminergic defect...? This appears to be novel approach. My only hesitation with Sibia (again from a VERY brief scan - please correct me) was flagged by the info in your post: you list too many diseases. Curing one symptom of one of those ailments would be a highly lucrative breakthrough and would be reason enough to own the stock. This may be the case with Sibia. But neurobiology does not live and die by the nicotinic cholinergic receptor. Here's the link to Peter's post: exchange2000.com Anyone want to take a stab at it? Baird

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next